|
|
|
24 Oct 2008 |
Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor
|
|
24 Oct 2008 |
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors
|
|
24 Oct 2008 |
Infinity's Hedgehog Pathway Inhibitor IPI-926 Demonstrates Significant Tumor Growth Inhibition in Human Pancreatic Cancer Model
|
|
24 Oct 2008 |
Infinity Initiates International Phase 3 Registration Trial of IPI-504 in Patients With Refractory GIST
|
|
23 Oct 2008 |
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
|
|
23 Oct 2008 |
Exelixis Retains Rights to Develop and Commercialize XL184
|
|
23 Oct 2008 |
Cougar Biotechnology Presents Positive CB7630 Phase II Data at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference
|
|
23 Oct 2008 |
Proteolix Presents Solid Tumor Clinical Trial Results for Carfilzomib at EORTC-NCI-AACR International Conference
|
|
23 Oct 2008 |
Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
Exelixis Reports Positive Phase 1 Data for XL281 at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
PharmaMar presents new data of Zalypsis® and Irvalec® in pediatric, solid tumours and lymphoma at the 20th AACR-NCI-EORTC Symposium
|
|
23 Oct 2008 |
Curis Announces Preclinical Efficacy Data for CUDC-305 at EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data at the EORTC-NCI-AACR Symposium
|
|
23 Oct 2008 |
Cytokinetics Announces Data Relating to GSK-923295 and SB-743921 Presented at the 2008 EORTC-NCI-AACR International Symposium
|
|
23 Oct 2008 |
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
|
|
23 Oct 2008 |
EntreMed’s ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
|
|
23 Oct 2008 |
Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical Study
|
|
23 Oct 2008 |
SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
|
|
23 Oct 2008 |
Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
|
|
22 Oct 2008 |
Preclinical Data Show Anti-Tumor Activity With Infinity's Oral Hsp90 Inhibitor IPI-493
|
|
22 Oct 2008 |
Boehringer Ingelheim broadens oncology pipeline with promising new data for potentially first in class Plk1 inhibitor
|
|
22 Oct 2008 |
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
|
|
22 Oct 2008 |
Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
|
|
22 Oct 2008 |
Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics' Demonstrate Superior Profile of S*BIO's Novel Anti-Cancer Drug SB939
|
|
22 Oct 2008 |
AngioChem's ANG1005 Demonstrates Preliminary Clinical Safety and Tolerability in Brain Cancer Patients
|
|
22 Oct 2008 |
Threshold Pharmaceuticals Presents Encouraging Additional Preliminary Findings From a Phase 1 Clinical Trial of TH-302 for Solid Tumors
|
|
21 Oct 2008 |
Nerviano Medical Sciences Announces a New Collaboration Agreement With Genentech to Discover Antibody Drug Conjugates
|
|
21 Oct 2008 |
4SC reports on positive results from a clinical phase I trial with cancer drug candidate 4SC-201
|
|
20 Oct 2008 |
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
|
|
20 Oct 2008 |
Geron Initiates Clinical Trial of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
|
|
20 Oct 2008 |
Ariad Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Prostate Cancer
|
|
20 Oct 2008 |
MediGene Reports Positive Final Results from EndoTAG™-1 Phase II Study in Pancreatic Cancer
|
|
16 Oct 2008 |
Immutep Announces IND Allowance in Pancreatic Cancer
|
|
16 Oct 2008 |
Piramal Life Sciences begins Phase II trial of P276 for head and neck cancer
|
|
16 Oct 2008 |
Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results
|
|
16 Oct 2008 |
FDA Grants Full Approval to ONTAK(R) (denileukin diftitox)For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
|
|
16 Oct 2008 |
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma
|
|
16 Oct 2008 |
Exelixis Submits Diligence Report for Cdc7 Inhibitor to Bristol-Myers Squibb
|
|
16 Oct 2008 |
Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar(R) (sorafenib) in Patients with Advanced Cancer
|
|
16 Oct 2008 |
Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar(R) (sorafenib) in Patients with Advanced Cancer
|
|
16 Oct 2008 |
Infinity Initiates Phase 1 Trial of Novel Hedgehog Pathway Inhibitor, IPI-926
|
|
16 Oct 2008 |
Patient inclusion started in phase III Oral Mucositis study
|
|
15 Oct 2008 |
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
|
|
15 Oct 2008 |
ATL1101 suppresses tumour growth in key mouse models of prostate cancer
|
|
15 Oct 2008 |
Geron's GRN163L Sensitizes Resistant Breast Cancer Cells to Trastuzumab in Preclinical Study
|
|
15 Oct 2008 |
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics
|
|
13 Oct 2008 |
Piramal Life Sciences receives DCGI Approval to conduct Phase I Trial of New Cancer Molecule P-1446A-05 in India
|
| |
|
Results 51 - 100 of 2757 |
